Cell Therapy Technologies Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Cell Therapy Technologies Market

Cell Therapy Technologies Market Size, Share & Trends by Product (Media, Sera & Reagents, Cell Culture Vessels, Single-Use Equipment), Process (Cell Processing, Preservation), Cell type (T-Cells, Stem cells), End User (Biopharma, CROs, CMOs), Region - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT
Report Code: BT 6823 Jul, 2023, by marketsandmarkets.com

The cell therapy technologies market, valued at $4.2 billion in 2023, is projected to grow to $7.8 billion by 2028, at a CAGR of 13.3%. The market is driven by rising government and private investments in cell-based research, the increasing incidence of chronic and infectious diseases, and the growing focus on personalized medicine. Key players such as Thermo Fisher Scientific, Merck KGaA, Lonza, Sartorius AG, and Danaher dominate the industry, making it challenging for smaller entrants. The market is segmented by product types, cell types, processes, and end-users, with biopharmaceutical and biotechnology companies leading the end-user segment. North America holds the largest market share due to the presence of major industry players and strong government support for research. Recent collaborations, such as those between Thermo Fisher and Arsenal Biosciences, and Danaher with the University of Pennsylvania, are driving innovation in manufacturing processes for cell therapies.

Cell Therapy Technologies Market Trends

Cell Therapy Technologies Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cell Therapy Technologies Market

Cell Therapy Technologies Market Dynamics

DRIVER: Rising incidence of chronic and infectious diseases

Cell therapy plays a crucial role in providing diagnostic and prognostic information for various diseases, including HIV/AIDS, cancer, and infectious diseases. Through innovative cellular-based approaches, it enables researchers and healthcare professionals to gain insights into disease mechanisms, disease progression, and treatment responses. The global population growth, climate change, and increased interaction between humans and animals have created an environment where the emergence of new virus outbreaks is more likely. Cell therapy research and applications are vital in addressing these challenges by providing advanced diagnostic tools, therapeutic interventions, and a deeper understanding of disease mechanisms.

RESTRAINT: High cost of cell-based research and low success rate

Cell biology research focuses on developing new therapies like stem cell and gene therapies. To obtain accurate results, high-quality instruments, reagents, and related products are essential. However, meeting regulatory guidelines and maintaining stringent quality standards in cell biology research incurs high costs. This poses a challenge for institutes and small-scale companies with limited budgets, as they may struggle to afford expensive research products.

OPPORTUNITY: Increased focus on personalized medicine

Precision medicine is an evolving approach to disease treatment and prevention that considers individual differences in genes, environment, and lifestyle. It involves tailoring drug selection to each patient based on their specific condition and medical history. While its application expands to various diseases, oncology has made notable progress in precision medicine. This personalized approach to diagnosis, treatment, and prevention utilizes comprehensive patient information, including genetics, environment, and lifestyle, to make more accurate decisions.

CHALLENGE: Survival of small players and new entrants

Small players and new entrants in the market face a significant challenge in terms of survival. Such as Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), Sartorius AG (Germany), and Danaher (US) account for a major share of the market. This makes it challenging for smaller players and new entrants to compete effectively. Additionally, the market demands substantial investments in research and development (R&D) and the launch of innovative products, creating difficulties for smaller players to sustain their operations and compete with established players that have substantial R&D budgets.

Cell Therapy Technologies Market Ecosystem

Cell Therapy Technologies Market Ecosystem

The process segment dominated the cell therapy technologies industry in 2022.

Based on process, the global cell therapy technologies market is segmented into cell processing cell preservation, distribution and handling, process monitoring and quality control. Cell processing segment dominated process segment in 2022. Availability and launch of technologically advanced cell processing equipment is likely to contribute to the growth of the segment.

The biopharmaceutical & biotechnology companies segment accounted for the segment dominated cell therapy technologies industry in 2022.

Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CRO’s & CMOs, research institutes and cell banks. In 2022, biopharmaceutical and biotechnology companies held dominant share owing to various factors such as increased investment in development of cell based therapies. Rising research institutes and biopharma companies collaborations is further anticipated to drive the growth of the segment at faster pace.

North America held a dominant share in the regional market for the cell therapy technologies industry in 2022.

Cell Therapy Technologies Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the cell therapy technologies markets are segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2022, North America accounted for the largest share of the market, followed by Europe & Asia Pacific. The region's dominant position can be attributed to several key factors such as presence of leading market players and increased government investments in cell-based research.

Key players in the cell therapy technologies market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany) and among others.

Scope of the Cell Therapy Technologies Industry

Report Metric

Details

Market Revenue Size in 2023

$4.2 billion

Projected Revenue Size by 2028

$7.8 billion

Industry Growth Rate

Poised to Grow at a CAGR of 13.3%

Market Driver

Rising incidence of chronic and infectious diseases

Market Opportunity

Increased focus on personalized medicine

This report categorizes the cell therapy technologies market to forecast revenue and analyze trends in each of the following submarkets:

By Product
  • Media, Sera, Reagents
  • Cell Engineering products
  • Cell Culture Vessels
  • Cell therapy Equipment
    • Cell Processing Equipment
    • Single Use Equipment
    • Other Equipment
  • System & Software
  • Other Products
By Cell Type
By Cell Process
  • Cell Processing
  • Cell Preservation, Distribution, and Handling
  • Process Monitoring and Quality Control
By End User
  • Biopharmaceutical & Biotechnology companies
  • CRO’s & CMO’s
  • Research Institutes & Cell Banks
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Recent Developments of Cell Therapy Technologies Industry:

  • In March 2023, Thermo fisher scientific Inc. entered into collaboration with Arsenal biosciences Inc. The collaboration allows development of manufacturing process for new cancer treatments. This research and process development-focused collaboration has enabled ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells for the treatment of cancer.
  • In March 2023, Danaher entered into partnership with the University of pennsylvania's center for cellular immunotherapies to solve manufacturing difficulties that are affecting the adoption of cell therapies.
  • In March 2023, Lonza and Vertex have entered a strategic collaboration to facilitate the manufacturing of Vertex's portfolio of investigational stem cell-derived islet cell therapies. As part of the collaboration, Vertex and Lonza will establish a dedicated manufacturing facility specifically for T1D cell therapies.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 33)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 RESEARCH LIMITATIONS 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
    1.7 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 CELL THERAPY TECHNOLOGIES INDUSTRY SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
          FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER)
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS 
          FIGURE 8 MARKET: CAGR PROJECTIONS, 2023–2028
          FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 49)
    FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 CELL THERAPY TECHNOLOGIES INDUSTRY, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 MARKET: GEOGRAPHIC SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 
          FIGURE 16 INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES
    4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES INDUSTRY, BY PRODUCT AND COUNTRY (2022) 
          FIGURE 17 T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 MARKET SHARE, BY PRODUCT, 2023 VS. 2028 
          FIGURE 18 MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028
    4.4 MARKET SHARE, BY END USER, 2022 (USD MILLION) 
          FIGURE 19 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022
    4.5 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 
          FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing government investments in cell-based research
                                TABLE 4 NIH FUNDING FOR CELL-BASED RESEARCH, 2019–2022 (USD MILLION)
                    5.2.1.2 Rising incidence of chronic and infectious diseases
                    5.2.1.3 Large number of oncology-related cell therapy clinical trials
                                FIGURE 22 CANCER CELL THERAPY PIPELINE, 2021–2022
                    5.2.1.4 Increasing GMP certifications for cell therapy production facilities
                                TABLE 5 EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of cell-based research and low success rate
                                TABLE 6 COST OF CELL THERAPY EQUIPMENT
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emergence of iPSCs as alternatives to ESCs
                    5.2.3.2 Increased focus on personalized medicine
                    5.2.3.3 Increasing partnerships for development of cell therapies
                    5.2.3.4 Emerging Asian markets
           5.2.4 CHALLENGES
                    5.2.4.1 Survival of small players and new entrants
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS
    5.4 INDICATIVE PRICING MODEL ANALYSIS 
          TABLE 7 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
    5.5 TECHNOLOGY ANALYSIS 
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 24 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
    5.7 SUPPLY CHAIN ANALYSIS 
          FIGURE 25 CELL THERAPY TECHNOLOGIES INDUSTRY: SUPPLY CHAIN ANALYSIS
    5.8 ECOSYSTEM ANALYSIS OF MARKET 
          FIGURE 26 ECOSYSTEM ANALYSIS
          TABLE 8 SUPPLY CHAIN ECOSYSTEM
    5.9 KEY CONFERENCES AND EVENTS IN 2022–2023 
          TABLE 9 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.10 REGULATORY ANALYSIS 
           5.10.1 REGULATORY LANDSCAPE FOR CELL THERAPIES
                     TABLE 10 NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES
                     TABLE 11 EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES
                     TABLE 12 ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES
                     TABLE 13 ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES
           5.10.2 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.11 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 19 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF SUPPLIERS
           5.11.4 BARGAINING POWER OF BUYERS
           5.11.5 DEGREE OF COMPETITION
    5.12 PATENT ANALYSIS 
           FIGURE 27 PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013–JULY 2023
           TABLE 20 MARKET: INDICATIVE LIST OF PATENTS
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS
           5.13.2 BUYING CRITERIA FOR CELL THERAPY PRODUCTS
                     FIGURE 29 KEY BUYING CRITERIA FOR END USERS
 
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT (Page No. - 81)
    6.1 INTRODUCTION 
          TABLE 21 CELL THERAPY TECHNOLOGIES INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 MEDIA, SERA, AND REAGENTS 
           6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
                    TABLE 22 MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 23 NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 CELL ENGINEERING PRODUCTS 
           6.3.1 AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
                    TABLE 26 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
                    TABLE 27 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 28 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 CELL CULTURE VESSELS 
           6.4.1 WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS
                    TABLE 31 CELL CULTURE VESSELS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 32 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 CELL THERAPY EQUIPMENT 
          TABLE 35 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 36 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 37 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021–2028 (USD MILLION)
          TABLE 38 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 39 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.5.1 CELL PROCESSING EQUIPMENT
                    6.5.1.1 Cell processing equipment to dominate market
                                TABLE 40 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 41 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 42 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 43 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.5.2 SINGLE-USE EQUIPMENT
                    6.5.2.1 Benefits of single-use equipment to ensure end-user demand
                                TABLE 44 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 45 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 46 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 47 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.5.3 OTHER EQUIPMENT
                    TABLE 48 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.6 SYSTEMS & SOFTWARE 
           6.6.1 NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND
                    TABLE 52 SYSTEMS & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 53 NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.7 OTHER PRODUCTS 
          TABLE 56 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 57 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 58 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 59 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS (Page No. - 100)
    7.1 INTRODUCTION 
          TABLE 60 CELL THERAPY TECHNOLOGIES INDUSTRY, BY PROCESS, 2021–2028 (USD MILLION)
    7.2 CELL PROCESSING 
           7.2.1 CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028
                    TABLE 61 MARKET FOR CELL PROCESSING, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: MARKET FOR CELL PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 CELL PRESERVATION, DISTRIBUTION, AND HANDLING 
           7.3.1 INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH
                    TABLE 65 MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 66 NORTH AMERICA: MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 EUROPE: MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 PROCESS MONITORING & QUALITY CONTROL 
           7.4.1 NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION
                    TABLE 69 MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 70 NORTH AMERICA: MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 71 EUROPE: MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 ASIA PACIFIC: MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE (Page No. - 108)
    8.1 INTRODUCTION 
          TABLE 73 CELL THERAPY TECHNOLOGIES INDUSTRY, BY CELL TYPE, 2021–2028 (USD MILLION)
    8.2 T CELLS 
           8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
                    TABLE 74 MARKET FOR T CELLS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 75 NORTH AMERICA: MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 EUROPE: MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 ASIA PACIFIC: MARKET FOR T CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 STEM CELLS 
           8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
                    TABLE 78 MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 79 NORTH AMERICA: MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 EUROPE: MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 ASIA PACIFIC: MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER CELLS 
          TABLE 82 MARKET FOR OTHER CELLS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 83 NORTH AMERICA: MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 84 EUROPE: MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 85 ASIA PACIFIC: MARKET FOR OTHER CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CELL THERAPY TECHNOLOGIES MARKET, BY END USER (Page No. - 116)
    9.1 INTRODUCTION 
          TABLE 86 CELL THERAPY TECHNOLOGIES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET
                    TABLE 87 MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 88 NORTH AMERICA: MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 EUROPE: MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 90 ASIA PACIFIC: MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 CROS & CMOS 
           9.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
                    TABLE 91 MARKET FOR CROS & CMOS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 92 NORTH AMERICA: MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 93 EUROPE: MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 94 ASIA PACIFIC: MARKET FOR CROS & CMOS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 RESEARCH INSTITUTES & CELL BANKS 
           9.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
                    TABLE 95 MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 96 NORTH AMERICA: MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 97 EUROPE: MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 98 ASIA PACIFIC: MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 CELL THERAPY TECHNOLOGIES MARKET, BY REGION (Page No. - 124)
     10.1 INTRODUCTION 
             TABLE 99 CELL THERAPY TECHNOLOGIES INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
                        TABLE 100 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 101 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 103 NORTH AMERICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 104 NORTH AMERICA: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 105 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Increasing R&D activities to support market growth
                                      TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 108 US: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 109 US: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 110 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments
                                      TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 113 CANADA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 114 CANADA: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 115 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 117 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 119 EUROPE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 120 EUROPE: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 121 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Germany to hold largest share of European market
                                      TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 124 GERMANY: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 125 GERMANY: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 126 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Favorable funding and investment scenario to drive market
                                      TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 129 UK: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 130 UK: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 131 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Availability of government and private support to drive market
                                      TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 133 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 134 FRANCE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 135 FRANCE: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 136 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Initiatives favoring cell and gene therapy development to support market growth
                                      TABLE 137 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 138 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 139 ITALY: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 140 ITALY: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 141 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Increasing funding from private and public organizations to aid market growth
                                      TABLE 142 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 143 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 144 SPAIN: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 145 SPAIN: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 146 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 147 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 148 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 149 REST OF EUROPE: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 150 REST OF EUROPE: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 151 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 31 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 152 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 153 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 154 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 155 ASIA PACIFIC: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 156 ASIA PACIFIC: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 157 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing cell therapy-based trials to support market growth
                                      TABLE 158 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 159 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 160 CHINA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 161 CHINA: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 162 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Rising geriatric population and growing disease prevalence to drive market
                                      TABLE 163 JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022
                                      TABLE 164 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 165 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 166 JAPAN: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 167 JAPAN: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 168 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Favorable government regulations to support market growth
                                      TABLE 169 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 170 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 171 INDIA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 172 INDIA: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                                      TABLE 173 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                        TABLE 174 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 175 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 176 REST OF ASIA PACIFIC: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 177 REST OF ASIA PACIFIC: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 178 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET
             10.5.2 LATIN AMERICA: RECESSION IMPACT
                        TABLE 179 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 180 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 181 LATIN AMERICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 182 LATIN AMERICA: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 183 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET
             10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 184 MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 185 MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 186 MIDDLE EAST & AFRICA: MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 187 MIDDLE EAST & AFRICA: MARKET, BY CELL TYPE, 2021–2028 (USD MILLION)
                        TABLE 188 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 169)
     11.1 INTRODUCTION 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 32 CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS 
             FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 34 CELL THERAPY TECHNOLOGIES INDUSTRY: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
             TABLE 189 CELL THERAPY TECHNOLOGIES INDUSTRY: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION MATRIX, 2022 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 35 CELL THERAPY TECHNOLOGIES INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
     11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 
             11.6.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
                        TABLE 190 PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS
             11.6.2 COMPANY PROCESS FOOTPRINT (25 COMPANIES)
                        TABLE 191 PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS
             11.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES)
                        TABLE 192 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
     11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 
             11.7.1 PROGRESSIVE COMPANIES
             11.7.2 STARTING BLOCKS
             11.7.3 RESPONSIVE COMPANIES
             11.7.4 DYNAMIC COMPANIES
                        FIGURE 36 CELL THERAPY TECHNOLOGIES INDUSTRY: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
     11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 
             TABLE 193 CELL THERAPY TECHNOLOGIES INDUSTRY: DETAILED LIST OF KEY START-UP/SME PLAYERS
             TABLE 194 CELL THERAPY TECHNOLOGIES INDUSTRY: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
     11.9 COMPETITIVE SCENARIO AND TRENDS 
             11.9.1 PRODUCT LAUNCHES
                        TABLE 195 CELL THERAPY TECHNOLOGIES INDUSTRY: PRODUCT LAUNCHES, JANUARY 2020–APRIL 2023
             11.9.2 DEALS
                        TABLE 196 CELL THERAPY TECHNOLOGIES INDUSTRY: DEALS, JANUARY 2020–APRIL 2023
             11.9.3 OTHER DEVELOPMENTS
                        TABLE 197 CELL THERAPY TECHNOLOGIES INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2020–APRIL 2023
 
12 COMPANY PROFILES (Page No. - 186)
     12.1 KEY MARKET PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 198 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
             12.1.2 MERCK KGAA
                        TABLE 199 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.3 DANAHER CORPORATION
                        TABLE 200 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.4 LONZA GROUP
                        TABLE 201 LONZA GROUP: BUSINESS OVERVIEW
                        FIGURE 40 LONZA GROUP: COMPANY SNAPSHOT (2022)
             12.1.5 SARTORIUS AG
                        TABLE 202 SARTORIUS AG: BUSINESS OVERVIEW
                        FIGURE 41 SARTORIUS AG: COMPANY SNAPSHOT (2022)
             12.1.6 TERUMO BCT, INC.
                        TABLE 203 TERUMO BCT, INC: BUSINESS OVERVIEW
                        FIGURE 42 TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)
             12.1.7 BECTON DICKINSON AND COMPANY
                        TABLE 204 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 43 BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             12.1.8 FRESENIUS SE & CO. KGAA
                        TABLE 205 FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW
                        FIGURE 44 FRESENIUS SE & CO: COMPANY SNAPSHOT (2022)
             12.1.9 AVANTOR, INC.
                        TABLE 206 AVANTOR, INC.: BUSINESS OVERVIEW
                        FIGURE 45 AVANTOR, INC.: COMPANY SNAPSHOT (2022)
             12.1.10 BIO-TECHNE
                        TABLE 207 BIO-TECHNE: BUSINESS OVERVIEW
                        FIGURE 46 BIO-TECHNE: COMPANY SNAPSHOT (2022)
             12.1.11 CORNING INCORPORATED
                        TABLE 208 CORNING INCORPORATED: BUSINESS OVERVIEW
                        FIGURE 47 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
             12.1.12 FUJIFILM IRVINE SCIENTIFIC
                        TABLE 209 FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 48 FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022)
             12.1.13 MAXCYTE, INC.
                        TABLE 210 MAXCYTE, INC.: BUSINESS OVERVIEW
                        FIGURE 49 MAXCYTE, INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS 
             12.2.1 WERUM IT SOLUTIONS
             12.2.2 ROOSTERBIO, INC.
             12.2.3 SIRION BIOTECH
             12.2.4 TRAKCEL
             12.2.5 L7 INFORMATICS, INC.
             12.2.6 MILTENYI BIOTEC B.V. & CO. KG
             12.2.7 STEMCELL TECHNOLOGIES
             12.2.8 GPI IBERIA (FORMERLY HEMASOFT)
             12.2.9 MAK-SYSTEM
             12.2.10 ORGANABIO
             12.2.11 IXCELLS BIOTECHNOLOGIES
             12.2.12 WILSON WOLF
 
13 APPENDIX (Page No. - 237)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the cell therapy technologies market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The top-down and other approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell therapy technologies market. Some of the key secondary sources referred to for this study include publications from government sources World Health Organization (WHO), the US Food and Drug Administration (FDA), the National Institutes of Health (NIH), the National Center for Biotechnology Information (NCBI). World Health Organization (WHO), CDC, International Society for Stem Cell Research, International Society for Cellular Therapy (ISCT), American Society of Gene & cell therapy (ASGCT), International cell Research Organization (ICRO), European Society of Gene and cell therapy (ESGCT), American Society for cell Biology, California Institute for Regenerative Medicine (CIRM), National Institute of Cancer (NIC), National Cancer Institute (NCI), Association of American Cancer Institutes (AACI).These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global cell therapy technologies market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cell Therapy Technologies Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the cell therapy technologies market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The major players in the industry and market have been identified through extensive primary and secondary research.
  • The revenues generated from the cell therapy technologies business of players operating in the market have been determined through secondary research and primary analysis.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach-

Cell Therapy Technologies Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After estimating the overall market size through the market size estimation process, the total market was further separated into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cell therapy refers to the introduction of new and healthy cells into the patient’s body to replace diseased or missing ones. New technologies and innovative products have enabled many different types of cells to treat diseases and conditions. Some of these cells are hematopoietic (blood-forming) stem cells (HSCs), skeletal muscle stem cells, mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells.

Cell therapy instruments are used in different cell processing stages, such as cell preservation & handling and process monitoring & quality control. These instruments are also used for clinical stem cell therapy and immunotherapy research & manufacturing.

Key Stakeholders

  • Manufacturers, importers & exporters, traders, distributors, and suppliers of cell therapy technologies
  • Cell therapy products manufacturers, suppliers, and processors
  • Distributors and suppliers of cell therapy products
  • Biotechnology and biopharmaceutical companies
  • Contract manufacturing organizations (CMOs)
  • Suppliers and distributors of pharmaceutical products
  • Research and development (R&D) companies
  • Pharmaceutical/medical associations
  • Trade associations and industry bodies
  • R Research institutes and government organizations
  • Venture capitalists and investors
  • Business research and consulting service providers
  • Market research and consulting firms regulatory bodies and government agencies

Report Objectives

  • To define, describe, segment, and forecast the cell therapy technologies market by product,  process, cell type, end user, and region
  • To provide detailed information about the factors influencing the market growth (drivers, restraints, opportunities, Challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall cell therapy technologies market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the cell therapy technologies market in four main regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
  • To profile the key players in the global cell therapy technologies market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments, such as product launches, funding and grants, partnerships, agreements, collaborations, expansions, strategic alliances, and acquisitions in the Cell therapy Technologies market.
  •  To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the Rest of Europe's Cell therapy technologies market, by country
  • Further breakdown of the Rest of Asia Pacific Cell therapy technologies market, by country
  • Further breakdown of the Rest of Latin America and Middle East & Africa Cell therapy technologies market, by country

Company Information

  • Detailed analysis and profiling of additional market top players (Up to 5)

Company Information

  • An additional five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 6823
Published ON
Jul, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cell Therapy Technologies Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback